CRYO-CELL International, Inc. (PK:CCEL)

Business Focus: Healthcare Facilities & Services

Sector:  Healthcare Industry:  Healthcare Facilities & Services
See Regulatory Filings on SEC
Company Contact
Address: 700 Brooker Creek Blvd Ste 1800
OLDSMAR FL 34677-2905
Tel: N/A
IR: See website
Key People
David I. Portnoy
Chairman of the Board, Co-Chief Executive Officer
Mark L. Portnoy
Co-Chief Executive Officer, Director
Jill M. Taymans
Chief Financial Officer, Vice President - Finance
Oleg Mikulinsky
Chief Information Officer
Business Overview
Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage. The Company's segments include cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacture of Prepacyte CB units, the processing technology used to process umbilical cord blood stem cells. The Company, in combination with its global affiliates, stores over 300,000 cord blood and cord tissue specimens around the world. The specimens are stored in commercially available cryogenic storage units at the facility in Oldsmar, Florida. The Company offers the cord tissue service in combination with the umbilical cord blood service. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives and other related healthcare professionals.
Financial Overview
For the nine months ended 31 August 2018, CRYO-CELL International, Inc. revenues increased 9% to $20.6M. Net income before extraordinary items decreased 24% to $1.2M. Revenues reflect Processing and storage fees increase of 11% to $19.7M. Net income was offset by Selling, general and administrative expe increase of 16% to $11.5M (expense), Interest expense increase of 6% to $995K (expense), Research.
Employees: 66 as of Nov 30, 2014
Reporting Currency: U.S. Dollars
Enterprise value: $69.44M as of Nov 30, 2018
Annual revenue (TTM): $27.10M as of Nov 30, 2018
EBITDA (TTM): $4.61M as of Nov 30, 2018
Net annual income (TTM): $4.92M as of Nov 30, 2018
Free cash flow (TTM): $5.95M as of Nov 30, 2018
Net Debt Last Fiscal Year: $6.70M as of Nov 30, 2018
Shares outstanding: 7,803,333 as of Feb 15, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization